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Abstract
Several international guidelines for the acute treatment of moderate to severe unipolar depression recommend a
first-line treatment with antidepressants (AD). This is based on the assumption that AD obviously outperform
placebo, at least in the case of severe depression. The efficacy of AD for severe depression can only be definitely
clarified with individual patient data, but corresponding studies have only been available recently. In this paper, we
point out discrepancies between the content of guidelines and the scientific evidence by taking a closer look at the
German S3-guidelines for the treatment of depression. Based on recent studies and a systematic review of studies
using individual patient data, it turns out that AD are marginally superior to placebo in both moderate and severe
depression. The clinical significance of this small drug-placebo-difference is questionable, even in the most severe
forms of depression. In addition, the modest efficacy is likely an overestimation of the true efficacy due to
systematic method biases. There is no related discussion in the S3-guidelines, despite substantial empirical evidence
confirming these biases. In light of recent data and with their underlying biases, the recommendations in the S3-
guidelines are in contradiction with the current evidence. The risk-benefit ratio of AD for severe depression may be
similar to the one estimated for mild depression and thus could be unfavorable. Downgrading of the related grade
of recommendation would be a logical consequence.
Keywords: Depression, Pharmacological, Treatment, Antidepressants, Guidelines
Background
Guidelines may be crucial for adequate treatment if they
systematically and critically evaluate the evidence and
infer treatment recommendations in a rational and
transparent manner. This way, guidelines are an import-
ant interface between science and clinical practice. The
obvious benefit of guidelines vanishes if the recommen-
dations are misleading, for example because of biases in
the synthesis of the evidence [1, 2], or simply because
the evidence in the guidelines is outdated and conflicting
with current evidence. Correcting the discrepancies be-
tween the content of the guidelines and current evidence
is of utmost importance to avoid potentially harming
patients. This seems to be the case for the acute pharma-
cological treatment of unipolar depression (synonymous
to major depression), as we demonstrate in this article.
We will mainly focus on the German S3-guidelines from
2015 (with updates until March 2017) [3]. However, algo-
rithms in other guidelines are largely comparable, for ex-
ample in the guidelines of organizations such as RANZCP
(Australia and New Zealand) or NICE (UK) [4, 5], thus
our findings are relevant beyond Germany.
Methods
We reviewed the sections of the S3-guidelines about the
acute pharmacological treatment of unipolar depression
(sections 3.4.1. to 3.4.4) with two objectives. First, we
investigated if the data about the efficacy of antidepres-
sants (AD) is still in line with current meta-analytic
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evidence, and also if the clinical importance of the findings
is discussed. Since main arguments of the treatment rec-
ommendations rely heavily on the efficacy of AD for dif-
ferent levels of depression severity, we included a simple
systematic review of related efficacy studies based on indi-
vidual patient data. We therefore systematically searched
PubMed on November 21, 2018, using the following
terms: (“individual participant” OR “individual patient”
OR “participant level” OR “patient level” OR “individual
level”) AND (“meta” OR “meta-analysis”) AND (depres-
sion OR SSRI OR SNRI OR antidepressants OR “mood
disorder” OR “affective disorder”). This resulted in 185
hits. After screening the abstracts, 149 studies could be ex-
cluded because they obviously did not include relevant in-
formation. The remaining 36 studies were screened in
detail and 10 studies included primary information of
interest [6–15]. We also checked the references of these
studies and could find one more relevant study [16]. The
11 relevant studies are summarized in Table 2. The sec-
ond objective was to review if empirically supported
method-biases were adequately addressed as limitations in
the judgment of the evidence [17].
Results and discussion
Efficacy of antidepressants
Comparing the evidence in the guideline with current
evidence
In the S3-guidelines, the efficacy of antidepressants (AD)
in the acute treatment of major depression is summa-
rized as follows [3]:
To prove a clinically relevant efficacy of acute
antidepressant treatment in placebo-controlled trials,
a minimum improvement of 50% on established scales
(e.g., the Hamilton Rating Scale) is suggested […] In
these kinds of clinical trials with a maximum duration
of up to twelve weeks, the response rates mostly range
between 50 and 60%, the placebo response rates about
25–35% (p. 67).1
Thus, the difference in response rates between AD and
placebo is reported to be around 25%. This conclusion is
based on two outdated studies; a meta-analysis and a re-
view [18, 19]. The 25%-difference contradicts the results
from current meta-analyses which reported a difference
of about 10% [20, 21], with response rates of approxi-
mately 50 and 40% for AD and placebo, respectively
(Table 1). A common counter-argument is that response
rates for placebo have increased over the years, leading
to decreasing AD-placebo differences. This argument is
often based on an outdated meta-analysis of Walsh et al.
from 2002 [19]. However, a recent meta-analysis found
that the placebo-response rates did not increase from
1991 onwards [22]. Therefore, the 25–35% placebo re-
sponse rate and the approximately 25% difference in re-
sponse rates between AD and placebo reported in the
S3-guidelines substantially deviate from the current
evidence.
We also noted a discrepancy between the summary
statement regarding the efficacy of AD (50–60% re-
sponders on AD as compared to 25–35% on placebo) and
the two studies that were cited in support of this state-
ment [18, 19]. One study [18] claimed that “there is a far-
reaching agreement” that two-third of patients respond to
AD, but this is not supported by the referenced evidence
(Table 1). Furthermore, both cited studies reported differ-
ences in response rates between AD and placebo of only
20% and not 25%. In addition, it is surprising that the S3-
guidelines did not include meta-analyses that were already
available before the guidelines were updated and pub-
lished [6, 7, 23–28] (see Table 1). These newer meta-ana-
lyses found substantially lower differences in response
rates between AD and placebo than the reported 25%, and
also much higher placebo response rates. Thus, even with-
out the latest meta-analyses published after 2017, the
overall assessment of efficacy should have been different.
The impression of an exaggerated presentation of the
efficacy of AD also occurs in the discussion of the effi-
cacy of different types of AD. For SSRIs, the following is
claimed:
The group of selective serotonin-reuptake-inhibitors (SSRI)
[…] increases the central serotonergic neurotransmission
by selectively inhibiting the reuptake of serotonin from the
synaptic cleft. This explains the antidepressant effects as
well as the side effects. The efficacy of selective serotonin
reuptake inhibitors (SSRIs) in the treatment of acute
depressive episodes has been demonstrated in many
clinical studies versus placebo and in corresponding
meta-analyses. (p. 69).
Some of the SSRI-trials cited in the S3-guidelines re-
ported rather small effect-sizes and this should have
raised doubts on the summary efficacy statement men-
tioned above. More importantly, the largest and most re-
cent meta-analysis cited in the S3-guidelines [27]
reported a high response rate for placebo (41–47%),
which grossly deviates from the summary statement
(25–35%).
One reason why recent meta-analyses reported smaller
differences between AD and placebo lies in the fact that
they were based on both published and unpublished stud-
ies, whereas earlier meta-analyses exclusively relied on
studies published in scientific journals [20, 21, 30]. A re-
lated well known publication bias is that positive
1All quotations from the S3-guidelines were translated into English by
the authors.
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studies were almost always published in scientific
journals (sometimes multiple times), but negative tri-
als were rarely published [31, 32]. According to a
comprehensive analysis of the trial-results available to
the FDA, only 51% of studies were positive and 97%
of these studies were published as positive studies in
journals. In contrast, only 3% of negative studies were
published as being negative in a journal. Furthermore,
21% of negative studies were published as being posi-
tive, for example by only reporting on a secondary
outcome that was then falsely reported to be the pri-
mary outcome, or by only reporting the results of a
subgroup. All other negative studies remained unpub-
lished [32]. Thus, despite that only about half of the
AD-trials were positive, nearly all related published
studies report positive findings [33]. This important
bias is briefly mentioned in the S3-guidelines, but the
implications are not considered any further in the
evaluation of the evidence from published AD trials.
One common explanation for the modest efficacy of
AD in more recent studies is that there is a trend to only
include less severely depressed patients or those without
frequent prior depressive episodes [5] (p. 308). However,
this does not seem to be the case, instead, it was the rate
of drop-outs due to inefficacy in placebo-groups that has
changed [34]. The average drop-out rate in the year
1985 was 58% and of those who discontinued the studies
early, 93% stated lack of efficacy as a reason. In the year
2009, only 20% of patients in the placebo-group dropped
out, and only 15% attributed this to lack of efficacy [34].
The massive reduction of placebo-dropouts due to lack
of efficacy is crucial, because this can fully explain the
reduced efficacy of AD in more recent studies. Moreover,
this effect appears to be robust and consistent, as it is in-
dependent of the length of the study or sample-size. Thus,
instead of the typical explanation that the placebo-re-
sponse is miraculously greater in more recent studies, a
more accurate interpretation is that patients on placebo
Table 1 Meta-analyses about the efficacy of AD compared to placebo
Response Rates (at least 50% reduction in depression)
AD (%) Placebo (%) Difference
S3-guidelines summary statement on efficacy
these were based on:
50–60 25–35 ca. 25
1. Walsh et al. (2002) [19] 50 30 20
2. Oeljeschläger et al. (2004) [18]a 67 47 20
Current Meta-Analyses
Cipriani et al. (2018) [20]b ca. 50 ca. 40 ca. 10
Jakobsen et al. (2017) [21]c 49 39 10
Meta-Analyses available before the last update of the S3-guidelines
Furukawa et al. (2016) [23] 35–40
Weitz et al. (2015) [24] 42 (Duloxetine) 45 (SSRIs) 24 18–21
Nelson et al. (2013) [7] 49 40 9
Gibbons et al. (2012) [6]
mild depression 55 37 18
severe depression 58 41 17
Undurraga & Baldessarini (2012) [25] 54 37 17
Melander et al. (2008) (SSRI + SNRI) [26] 48 32 16
Arroll et al. (2005) [27] SSRI: 56 41 15
TCI: 60 47 13
Storosum et al. (2004) (only TCA) [28] 39 28 11
Notes
a This review claims a “far-reaching agreement” that two-third respond when treated with AD, whereas there are 20% less responders under placebo, referencing
a review of Bauer et al. (2002). The Bauer et al. review, in return, reported a response rate of 50–75% for the old generation AD for medium to severe depression
and of 25–33% for placebo (based on a review of the American Psychiatric Association from the year 2000), as well as a response rate of 50% for SSRIs and of
32% for placebo (based on a report from the Agency for Health Care Policy and Research from the year 1999). Thus, the conclusions not only deviate from the
cited sources, but these sources are also outdated, since they were published at least 15 years before the publishing of the S3-guidelines
b Cipriani et al. did not report response rates, but they were estimated elsewhere [29], using an average effect of OR = 1.66 and a response rate of 30–40% for
placebo. We also tried to estimate the difference between the AD and placebo response rates, using the results from Jakobsen et al. (2017) [21] who reported
39% responders under placebo. With the average effect of OR = 1.66, we came up with nearly identical results (51% responders under AD and 39% under
placebo). Formula: RAD = OR*Rp/(1-Rp + OR*Rp). RAD: response rate AD, Rp: response rate placebo
c based on the results for nonresponse
Plöderl and Hengartner BMC Psychiatry          (2019) 19:265 Page 3 of 9
do not immediately drop-out if they do not recognize
some effect of the drug [34] (this also raises the question
of successful blinding of patients and doctors in older tri-
als). Since patients could be kept longer in more recent
studies, it seems that substantially more patients in the
placebo-group achieve spontaneous remission until the
end of the trial, leading to a reduction of the difference be-
tween AD and placebo, even when they may not perceive
a drug effect.
Discussion of clinical significance
There is a controversy about the appropriateness of
using response rates, because this can lead to an over-
estimation of the efficacy of a treatment [35] (also see
footnote 2). This problem is briefly mentioned in the S3-
guidelines:
Furthermore, the efficacy in comparison to placebo is
mostly based on the higher response rate, whereas the
difference in remission-rates or the reduction of
summary-scores of depression rating-scales is often not
significant (p. 67).
However, it is not discussed what “not significant” ac-
tually implies. In the meantime, it has been replicated
many times that even though the AD-placebo difference
is statistically significant, this effect may not be clinically
significant [17, 21, 36]. This was already discussed in
publications available at the time well before the S3-
guidelines were published [35, 37, 38]. For example,
Kirsch and colleagues demonstrated that most variance
(> 75%) in the outcome in the SSRI groups can be attrib-
uted to placebo-responses, and the rest may result from
enhanced placebo responses due to perceived side-ef-
fects of AD [37]. According to the most recent meta-
analysis of Cipriani and colleagues [20], the overlap be-
tween AD and placebo is even larger (88%) [17, 39].
Admittedly, there is no universal definition of “clinical
significance” (see Footnote 2). However, AD do not meet
any criterion for clinical significance, not even the most
liberal [17, 39]. This is not surprising, because the aver-
age difference of AD compared to placebo is only about
2 points on the HAMD-17 depression rating scale that
has a range from 0 to 52 points (most items are scored
between 0 and 4). This is intuitively a very modest and
unimportant effect, which is also confirmed when the 2
point difference is compared to clinical judgments made
by mental health professionals. If the HAMD is com-
pared to the clinical evaluation using the Clinical Global
Impression Improvement Scale (CGI-I), then 0–3 points
improvement on the HAMD correspond to “no
improvement” on the CGI-I. It needs at least 7 points
improvement on the HAMD scale to achieve a
corresponding “minimal improvement” on the CGI-I.
None of the AD come anywhere near this criterion [17].
Furthermore, the S3-guidelines seem to have a contra-
dictory use of clinical significance, because it is questioned
in one section and then taken for granted in other sections.
When the efficacy of AD for mild depression is discussed
(p. 68), the criterion of 3 HAMD-points for clinical signifi-
cance is questioned with the argument that this criterion
was removed from the current NICE guidelines. This is
wrong, because the NICE guidelines from 2010 did include
this criterion in an appendix [5].2 Doubts on the criterion
for clinical significance also appear when discussing a study
which reported less than 3 HAMD-points difference
between AD and placebo for both mild and more severe
depression [6]. Interestingly, this important study is then
ignored in the following section (also p. 68) about the treat-
ment of moderate to severe depression. Instead, it is stated
that for severe depression, AD are clinically superior to pla-
cebo, based on the 3-point criterion for clinical significance.
Efficacy of AD in relation to depression severity – guidelines
versus current evidence from a systematic review
The S3-guidelines report that, for mild depression, AD are
not superior to placebo, resulting in an unfavorable nega-
tive risk-benefit ratio because of the side-effects of AD.
The NICE guidelines include very similar arguments: “Do
not use antidepressants routinely to treat persistent sub-
threshold depressive symptoms or mild depression be-
cause the risk-benefit ratio is poor (p. 327)” [5]. Likewise,
the RANZCP guidelines recommend that “patients with
mild-moderate depression should be offered one of the
evidence based psychotherapies as first line treatment”
(p. 1108) [4] (the negative risk-benefit ratio is not expli-
citly stated but the logical argument behind this conclu-
sion is given).
For moderate to severe depression, the S3-guidelines
report that AD have a clinically significant effect:
For medium to severe depression, however, the
difference in efficacy between antidepressants and
placebo is more pronounced, since in the most severe
2Unfortunately, the NICE guidelines did not justify the different
definitions of clinical significance. Three different criteria for clinical
significance were defined: First, a ≥ 3 points difference between AD
and placebo on the HAMD scale (or the BDI scale). Second, an effect-
size of d ≥ 0.5 (equivalent to approximately 3.8 points difference on
the HAMD scale [17]). Third, a risk-ratio (RR) of RR ≤ 0.8 for
response rates. Of note, these criteria are an absolute minimum,
corresponding to a “no improvement” clinical judgment, but this is not
mentioned. Furthermore, the three criteria are not equivalent, leading
to contradictory conclusions. For example, the average effect-size in a
recent meta-analysis [20] was d = 0.3 (clearly below the required
d = 0.5), corresponding to a 2.4 HAMD points difference (below the
required 3 points), but to a risk ratio of RR = 0.8 (only just fulfilling
the criterion).
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forms up to 30% of treated patients benefit from
antidepressants above the placebo rate. Thus, HDRS
scores of > 24 are associated with the most consistent
difference between the response to drug and placebo,
whereby these differences in the direction of the active
antidepressant are also clinically significant (p. 68).
This statement is based on a single citation, referring
to a study by Khan et al. (2005), but this study is not re-
lated to depression at all and is most likely a citation
error. We guess that the authors of the S3-guidelines
wanted to refer either to another publication of Khan
[40], or to the meta-analysis of Fournier et al. [9] that is
frequently cited in this context.
To clarify if AD are more efficacious for severely de-
pressed patients, individual-level data from patients are
needed, because using group means leads to substantial
biases (referred to as ecological fallacy) [41]. It is surprising
that this argument is completely lacking in the S3-guide-
lines, even more so, as two such studies with individual pa-
tient data were cited in the S3-guidelines, and these studies
addressed the problems resulting from group-level data [6,
9]. In addition, one of these studies did not find AD to be
clinically effective for severe depression [6], but this study
was not discussed appropriately, as we already noted above.
Our simple systematic review of studies with individual
patient-level data could locate 11 relevant studies that are
summarized in Table 2. It can be concluded that most pa-
tient-level meta-analyses, especially the more recent and
larger ones, reported that AD are not clinically signifi-
cantly superior to placebo, even for severe depression (< 3
HAMD-points difference between AD and placebo). One
exception is a study in older patients, where one subgroup
(severely and chronically depressed patients) responded
much better to AD than to placebo [7]. However, this
could be a false positive finding because of multiple testing
of many different subgroups. Also, according to the meta-
analysis of Fournier et al. [9], AD were substantially more
efficacious than placebo in patients with a baseline score
of ≥23 on the HAMD, but this was refuted in recent and
larger meta-analyses. One very recent study reported that
placebo is slightly more effective than AD for the most
severely depressed patients [15]. Finally, it was also found
that AD were not more efficacious for the melancholic
subtype of depression – which is associated with higher
depression-scores and seen as the most severe form of
depression by many experts [12].
Discussion of method biases
The S3-guidelines did not include a discussion of im-
portant biases, except for the publication bias:
In the perception of the (specialist) public, the efficacy
of antidepressants is rather overestimated, since
studies in which the antidepressant performed better
than placebo are published much more frequently in
scientific journals than those in which the
antidepressant was not superior to placebo (p. 67).
So the publication bias is briefly mentioned, but it was
not considered elsewhere. This is problematic in sections
where treatments were compared with each other, based
on single or very few published studies. Due to the pub-
lication and sponsorship bias, where negative results are
rarely published, these comparisons are likely biased
[43]. Moreover, throughout the guidelines, the efficacy
of different treatment approaches is often based on stat-
istical significance alone. It is known that statistical sig-
nificance is not informative about the size of a difference
or about clinical significance [39].
There are many more biases that may lead to an overesti-
mation of the efficacy of AD, but they were not discussed
in the S3-guidelines. Such biases include unblinding due to
specific side-effects of AD, exclusion of patients who im-
prove in the placebo lead-in phase, withdrawal effects in
the placebo group due to abrupt discontinuation of pre-trial
AD prescriptions, inadequate handling of missing data with
last observations-carried forward, and other biases [44–46].
Some of these biases, for example the breaking of the
double-blinding due to correct guessing of placebo or drug,
have been replicated in various empirical studies and are
known for a long time [47, 48]. There is also sound evi-
dence that unblinded physicians judge the drug as being
more effective than blinded physicians [49, 50]. Just re-
cently, it was found that trials with a placebo lead-in phase
produce significantly larger efficacy estimates than the mi-
nority of trials without such a lead-in phase (d = 0.31 vs.
d = 0.22) [51]. This was long expected by various experts,
because patients who improve during the placebo lead-in
phase are excluded from the trial, biasing the results in
favor of AD. Thus, it can be concluded with a high degree
of certainty, that the efficacy of AD is overestimated in typ-
ical clinical trials. In contrast, we are not aware of empirical
studies confirming postulated biases leading to an under-
estimation of the efficacy of AD [52, 53]. On the contrary,
some of these biases were refuted in the meantime. For
example, it is often claimed that AD work much better
in real-world patients. However, AD are no more ef-
fective in patients treated in the real-world routine
practice compared to those selected for clinical trials,
as clearly demonstrated in the STAR*D study [54, 55]
or in a meta-analysis of real-world primary care pa-
tients [56]. Some other assumed biases do not seem
very plausible, for example the argument that patients
lie about their depression to be included in studies in
order to obtain treatment for free or to receive some
money. Even if this is so, there is no plausible explan-
ation as to why this should lead to biased drug-placebo
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differences, since these malingerers would be randomly
assigned to treatment arms. In any case, there is no em-
pirical evidence that would support such an assumption,
and as such it is no more than an untested hypothesis.
Another popular argument is that some trials allow add-
itional treatment with benzodiazepines and other tranquil-
izers, but this would affect both the AD and the placebo
groups similarly, so this is no systematic bias and both dir-
ection and size of the bias are still unknown.
Conclusions
The S3-guidelines and other international guidelines do
not recommend AD as first-line treatment for mild de-
pression, because:
Due to the unfavorable risk-benefit ratio, antidepressants
are not generally useful in the initial treatment of mild
depressive episodes, since antidepressant medication is
hardly superior to a placebo condition (p. 74, citations
removed).
As we have shown in this paper and discussed else-
where [17, 39], AD are indeed hardly superior to placebo
in mild depression, but the same holds for moderate and
severe depression (i.e., less than three points on the
HAMD scale or approximately 10% difference in response
rates). This already modest efficacy is most likely an over-
estimation of the true effect size due to various systematic
method biases inherent in clinical trials. Therefore, the de-
gree of recommendation for the pharmacological acute
treatment of moderate and severe depression with AD
should be downgraded on the basis of the guidelines’ own
logic. We are not alone with such conclusions. Munkholm
et al. [51] recently re-analyzed the trial data for moderate
to severe depression collected by Cipriani et al. [20], and
based on the poor efficacy estimates and the many system-
atic biases in these trials, they concluded that “the evi-
dence does not support definitive conclusions regarding
the efficacy of antidepressants for depression in adults, in-
cluding whether they are more efficacious than placebo”
(p. 8). Consequently, this impacts the risk-benefit ratio of
AD in the acute treatment of major depression, as well as
comparisons of AD with alternative treatments. Therefore,
treatment recommendations should be critically discussed
in light of the current evidence. This clearly goes beyond
the scope of this paper, but good examples are available
[57]. We hope that our review can inform clinicians until
the guideline will be updated accordingly.
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